Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.9 USD | -4.17% | -0.29% | -30.30% |
Financials (USD)
Sales 2024 * | 31.31M | Sales 2025 * | 31.62M | Capitalization | 737M |
---|---|---|---|---|---|
Net income 2024 * | -140M | Net income 2025 * | -153M | EV / Sales 2024 * | 24.7 x |
Net Debt 2024 * | 34.45M | Net cash position 2025 * | 239M | EV / Sales 2025 * | 15.7 x |
P/E ratio 2024 * |
-5.35
x | P/E ratio 2025 * |
-5.28
x | Employees | 140 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.67% |
Latest transcript on Tango Therapeutics, Inc.
1 day | -4.17% | ||
1 week | -0.29% | ||
Current month | -0.29% | ||
1 month | -12.10% | ||
3 months | -37.39% | ||
6 months | -19.30% | ||
Current year | -30.30% |
Managers | Title | Age | Since |
---|---|---|---|
Barbara Weber
CEO | Chief Executive Officer | 67 | 17-02-28 |
Daniella Beckman
DFI | Director of Finance/CFO | 45 | 16-09-30 |
Jannik Andersen
CTO | Chief Tech/Sci/R&D Officer | - | 18-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alexis Borisy
CHM | Chairman | 52 | 16-12-31 |
Mace Rothenberg
BRD | Director/Board Member | 67 | 21-02-28 |
Barbara Weber
CEO | Chief Executive Officer | 67 | 17-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +9.52% | - | |
0.00% | 9 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 6.9 | -4.17% | 741,147 |
24-06-06 | 7.2 | -2.83% | 406,495 |
24-06-05 | 7.41 | +4.07% | 345,641 |
24-06-04 | 7.12 | +1.71% | 291,894 |
24-06-03 | 7 | +1.16% | 429,452 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.30% | 737M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- TNGX Stock